Disruption of the β2-integrin CD11d (αDβ2) gene fails to protect against experimental autoimmune encephalomyelitis

This publication has 40 references indexed in Scilit:

• A monoclonal antibody to CD11d reduces the inflammatory infiltrate into the injured spinal cord: a potential neuroprotective treatment
  Journal of Neuroimmunology, 2004
• P marks the spot: site-specific integrin phosphorylation regulates molecular interactions
  Trends in Biochemical Sciences, 2004
• An anti‐CD11d integrin antibody reduces cyclooxygenase‐2 expression and protein and DNA oxidation after spinal cord injury in rats
  Journal of Neurochemistry, 2004
• Transient Blockade of the CD11d/CD18 Integrin Reduces Secondary Damage after Spinal Cord Injury, Improving Sensory, Autonomic, and Motor Function
  Journal of Neuroscience, 2004
• A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
  New England Journal of Medicine, 2003
• Augmentation of adoptively transferred experimental allergic encephalomyelitis by administration of a monoclonal antibody specific for LFA-1α
  Journal of Neuroimmunology, 1993
• Treatment with anti‐CR3 antibodies ED7 and ED8 suppresses experimental allergic encephalomyelitis in Lewis rats
  European Journal of Immunology, 1993
• Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin
  Nature, 1992
• Tumor necrosis factor-induced degranulation in adherent human neutrophils is dependent on CD11b/CD18-integrin-triggered oscillations of cytosolic free Ca2+.
  Proceedings of the National Academy of Sciences, 1990
• Anti-macrophage CR3 antibody blocks myelin phagocytosis by macrophages in vitro
  Acta Neuropathologica, 1990